Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017

Abstract

Among U.S. men, prostate cancer is the second leading cause of cancer-related death (1). Past studies documented decreasing incidence of prostate cancer overall since 2000 but increasing incidence of distant stage prostate cancer (i.e., signifying spread to parts of the body remote from the primary tumor) starting in 2010 (2,3). Past studies described disparities in prostate cancer survival by stage, age, and race/ethnicity using data covering ≤80% of the U.S. population (4,5). To provide recent data on incidence and survival of prostate cancer in the United States, CDC analyzed data from population-based cancer registries that contribute to U.S. Cancer Statistics (USCS).* Among 3.1 million new cases of prostate cancer recorded during 2003-2017, localized, regional, distant, and unknown stage prostate cancer accounted for 77%, 11%, 5%, and 7% of cases, respectively, but the incidence of distant stage prostate cancer significantly increased during 2010-2017. During 2001-2016, 10-year relative survival for localized stage prostate cancer was 100%. Overall, 5-year survival for distant stage prostate cancer improved from 28.7% during 2001-2005 to 32.3% during 2011-2016; for the period 2001-2016, 5-year survival was highest among Asian/Pacific Islanders (API) (42.0%), followed by Hispanics (37.2%), American Indian/Alaska Natives (AI/AN) (32.2%), Black men (31.6%), and White men (29.1%). Understanding incidence and survival differences by stage, race/ethnicity, and age can guide public health planning related to screening, treatment, and survivor care. Future research into differences by stage, race/ethnicity, and age could inform interventions aimed at improving disparities in outcomes. Cases included males with malignant † prostate cancer § and excluded cases diagnosed by autopsy and death certificate only.

Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment

“…Cancer survival has improved for all Americans since the 1970s, and the gap for rates of prostate cancer incidence and survival between Black men and White has narrowed over the last 25 years (Figs. 1 and 2) [79–82]. Data before the USPSTF prostate cancer screening recommendation changes illustrate this era difference, as White men were less likely to die of prostate cancer than Black men [30].…”

“…Data before the USPSTF prostate cancer screening recommendation changes illustrate this era difference, as White men were less likely to die of prostate cancer than Black men [30]. A more recent analysis shows that the 5‐year overall survival rate, 2001–2016, for metastatic prostate cancer was 31.6% for Black men and 29.1% for White men [79]. However, only ongoing analyses will show if this trend continues, particularly in the years following the ongoing COVID‐19 pandemic.…”

Novel platinum bipolar electrode for irreversible electroporation in prostate cancer: preclinical study in the beagle prostate

“…Prostate cancer is the most common cancer diagnosed in men, with an estimated 248,530 newly diagnosed men in the United States in 2021 1 . Of the 3.1 million men newly diagnosed with prostate cancer in 2003–2017, 77% had localized prostate cancer 1 .…”

“…Prostate cancer is the most common cancer diagnosed in men, with an estimated 248,530 newly diagnosed men in the United States in 2021 1 . Of the 3.1 million men newly diagnosed with prostate cancer in 2003–2017, 77% had localized prostate cancer 1 . Randomized clinical trials have shown that, compared with watchful waiting, radical prostatectomy improves overall survival or delays the development of metastatic disease in men with localized prostate cancer 2 , 3 .…”

miR-499a inhibits the proliferation and apoptosis of prostate cancer via targeting UBE2V2

“…Prostate cancer is a malignant tumor with a very high incidence of the male urinary system [ 1 ]. The disease is caused by malignant tumor lesions in the epithelium of the prostate [ 2 ]. The main population is 70–80-year-old males.…”